Key events, in time order
Revenue $2.7B beat; adj EPS $3.60 beat; FY EPS guide raised to $12-$13
Multiple sources confirm diranersen missed primary endpoint but reduced tau and slowed cognitive decline by 26%, prompting Phase 3 advancement
FDA approves Leqembi Iqlik weekly at-home autoinjector, replacing biweekly IV infusion as starting regimen
FDA approves first anti-amyloid subcutaneous initiation dose; US launch planned late Aug
Multiple firms upgrade to Buy, citing optimism ahead of Alzheimer's drug data
None yet
None yet
The user suggests Biogen (BIIB) should have acquired another company, implying a missed strategic opportunity. The discussion is a retrospective fundamental thesis.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
Biogen makes drugs for brain and nerve diseases, like multiple sclerosis and spinal muscular atrophy, plus biosimilars that copy blockbuster biologics.
Money comes from selling MS drugs (TECFIDERA, TYSABRI, OCREVUS) and SMA treatment SPINRAZA, with gross margins around 68% and net margins near 8%.
Hard-to-replicate biologics and patents protect MS and SMA franchises, but Alzheimer's flop ADUHELM and biosimilar competition from Samsung Bioepis and Amgen erode pricing power.
Hold (sector percentile 58) — value B, growth C-, profitability B, momentum C+, revisions A-. Updated daily, sector-relative, identical for every user.
